MedTrace Logo

Vitamin C in Atrial Fibrillation Ablation

NCT03148236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

Single-center, double-blinded, randomized, controlled safety and feasibility pilot study of high dose IV ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered every six hours with a 30 minute IV infusion time per dose, compared to matched placebo infusion

Conditions

  • Atrial Fibrillation Ablation

Interventions

DRUG

Vitamin C

200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W

OTHER

Placebo

50mL infused over 30 minutes

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Jayanthe Koneru, MD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-18
Primary Completion
2018-03-13
Completion
2018-03-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03148236 on ClinicalTrials.gov